What is Immunome's D&A?

Immunome (IMNM) reported D&A of $603K in Q1 2026.

How has Immunome's D&A changed year-over-year?

Immunome's D&A decreased by 1.3% year-over-year, from $611K to $603K.

What is the long-term trend for Immunome's D&A?

Over 4 years (2021 to 2025), Immunome's D&A has grown at a 34.4% compound annual growth rate (CAGR), from $755K to $2.47M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Immunome IMNM D&A

D&A at other companies

PfizerPFE

$1.61B-0.3%

Arcus BiosciencesRCUS

$2M-33.3%

Nuvation BioNUVB

$536K+72.9%

ArriVent BioPharma, Inc.AVBP

-$559K+26.1%

IDEAYA Biosciences, Inc.IDYA

$688K+14.7%

ImmunityBio, Inc.IBRX

$4.38M+14.4%

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's D&A?: Immunome (IMNM) reported D&A of $603K in Q1 2026.
How has Immunome's D&A changed year-over-year?: Immunome's D&A decreased by 1.3% year-over-year, from $611K to $603K.
What is the long-term trend for Immunome's D&A?: Over 4 years (2021 to 2025), Immunome's D&A has grown at a 34.4% compound annual growth rate (CAGR), from $755K to $2.47M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.